Human monoclonal antibodies against CD25

A method of treating a lymphoid neoplasm involving T cells expressing CD25 in a patient, comprising administering to the patient an antibody that binds to human CD25 in an amount effective to treat the lymphoid neoplasm, wherein the antibody is selected from the group consisting of:

• (a) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs:
• 6 and 8, respectively;
• (b) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs:
• 14 and 16, respectively;
• (c) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs:
• 2 and 4, respectively;
• (d) an antibody comprising heavy and light chain variable region sequences set forth in SEQ ID NOs:
• 10 and 12, respectively;
• (e) an antibody comprising heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
• 35, 36, and 37, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
• 38, 39, and 40, respectively;
• (f) an antibody comprising heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
• 17, 18, and 19, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
• 20, 21, and 22, respectively;
• (g) an antibody comprising heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
• 23, 24, and 25, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
• 26, 27, and 28, respectively;
• and
• (h) an antibody comprising heavy chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
• 29, 30, and 31, respectively, and light chain CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
• 32, 33, and 34, respectively.